Research team
研究團(tuán)隊(duì)

您的(de)位置: 首頁(yè)> 研究團(tuán)隊(duì)> PI介紹

PI介紹

陸林宇
( 教授(shou) )
導(dao)師類型:博士生(sheng)導(dao)師 專(zhuan)業:分(fēn)子(zi)與細胞醫(yī)學(xué)、婦産(chan)科(ke)學(xué) 郵(you)箱地阯(zhi):lulinyu@zju.edu.cn
研究方(fang)向:
DNA損傷修複與生(sheng)殖細胞髮(fa)育

箇(ge)人(ren)簡介

陸林宇,浙江(jiang)大(da)學(xué)轉化醫(yī)學(xué)研究院/附屬婦産(chan)科(ke)醫(yī)院教授(shou),博士生(sheng)導(dao)師。課題組研究方(fang)向爲(wei)DNA損傷修複與生(sheng)殖細胞髮(fa)育,特别關注減數(shu)分(fēn)裂同源重(zhong)組。具(ju)體(ti)研究內(nei)容包括:1. DNA雙鏈斷(duan)裂修複與減數(shu)分(fēn)裂同源重(zhong)組(減數(shu)分(fēn)裂同源重(zhong)組的(de)分(fēn)子(zi)機(jī)製(zhi)、卵母細胞減數(shu)分(fēn)裂同源重(zhong)組檢(jian)查點的(de)關鍵信(xin)号通(tong)路與分(fēn)子(zi)機(jī)製(zhi)、精(jīng)母細胞減數(shu)分(fēn)裂前(qian)期獨特的(de)DNA雙鏈斷(duan)裂修複機(jī)製(zhi));2. DNA損傷修複與生(sheng)殖細胞維(wei)持(DNA損傷修複在(zai)精(jīng)原幹細胞自我(wo)更新(xin)與分(fēn)化中(zhong)的(de)作(zuò)用(yong)、DNA損傷修複缺陷導(dao)緻卵巢早衰的(de)分(fēn)子(zi)機(jī)製(zhi))。作(zuò)爲(wei)通(tong)訊作(zuò)者在(zai)NEJM、PNAS等(deng)雜志(zhì)上髮(fa)表研究成(cheng)果。


主(zhu)要科(ke)研項(xiang)目(mu)

  • 1. 國(guo)傢(jia)自然科(ke)學(xué)基金(面上項(xiang)目(mu)),32370900,BRCA1在(zai)卵母細胞減數(shu)分(fēn)裂同源重(zhong)組檢(jian)查點中(zhong)的(de)作(zuò)用(yong)機(jī)製(zhi)研究,2024.01-2027.12,50萬,在(zai)研,項(xiang)目(mu)負責人(ren);

  • 2. 國(guo)傢(jia)自然科(ke)學(xué)基金(面上項(xiang)目(mu)),32070829,DNA損傷修複蛋白BRCA1維(wei)持未分(fēn)化精(jīng)原細胞穩态的(de)機(jī)製(zhi)研究,2021.01-2024.12,58萬,在(zai)研,項(xiang)目(mu)負責人(ren);

  • 3. 國(guo)傢(jia)重(zhong)點研髮(fa)計(ji)劃,2016YFC1000600,人(ren)類配(pei)子(zi)髮(fa)生(sheng)、成(cheng)熟障礙與胚胎停育的(de)分(fēn)子(zi)機(jī)製(zhi),2016.7-2020.12,397.5萬,已結題,子(zi)課題負責人(ren);

  • 4. 國(guo)傢(jia)自然科(ke)學(xué)基金(面上項(xiang)目(mu)),81471494,BRCA1在(zai)男性精(jīng)母細胞減數(shu)分(fēn)裂中(zhong)的(de)作(zuò)用(yong),2015.01-2018.12,73萬,已結題,項(xiang)目(mu)負責人(ren);

代(dai)表性論文(wén)(#第一(yi)作(zuò)者,*通(tong)訊作(zuò)者)

  • 1. Tang Z, Liang Z, Zhang B, Xu X, Li P, Li L, Lu LY, Liu Y*. (2024) MRE11 is essential for the long-term viability of undifferentiated spermatogonia. Cell Proliferation, e13685.

  • 2. Bai L, Li P, Xiang Y, Jiao X, Chen J, Song L, Liang Z, Liu Y*, Zhu Y*, Lu LY*. (2024) BRCA1 safeguards genome integrity by activating chromosome asynapsis checkpoint to eliminate recombination-defective oocytes. PNAS,121(19):e2401386121.

  • 3. Xie C, Wang W, Tu C, Meng L, Lu G, Lin G, Lu LY, Tan YQ*. (2022) Meiotic recombination: insights into its mechanisms and its role in human reproduction with a special focus on non-obstructive azoospermia. Human Reproduction Update, 28(6):763-797.

  • 4. Li L, Tan YQ, Lu LY*. (2022) Defective piRNA Processing and Azoospermia. New England Journal of Medicine, 386(17):1675-1676.

  • 5. Liu Y*, Lu LY*. (2021) BRCA1: a key player at multiple stages of homologous recombination in DNA double-strand break repair. Genome Instability & Disease, 2(3):164–174. (Invited review)

  • 6. Liu K, Wang Y, Zhu Q, Li P, Chen J, Tang Z, Shen Y, Cheng X, Lu LY*, Liu Y*. (2020) Aberrantly expressed HORMAD1 disrupts nuclear localization of MCM8-MCM9 complex and compromises DNA mismatch repair in cancer cells. Cell Death & Disease, 11(7):519.

  • 7. Liu Y*, Lu LY*. (2020) BRCA1 and homologous recombination: implications from mouse embryonic development. Cell & Bioscience, 10:49. (Invited review)

  • 8. Chen J, Li P, Song L, Bai L, Huen MS, Liu Y*, Lu LY*. (2020) 53BP1 loss rescues embryonic lethality but not genomic instability of BRCA1 total knockout mice. Cell Death & Differentiation, 27(9):2552–2567.

  • 9. Zhang B, Tang Z, Li L, Lu LY*. (2020) NBS1 is required for SPO11-linked DNA double-strand break repair in male meiosis. Cell Death & Differentiation, 27(7):2176–2190.

代(dai)表性著作(zuò)

獲獎

  • 文(wén)章
  • 導(dao)師